Resources

• Category: Huntington's Disease, CHDI, HD-IH
• Date: 21/09/2022

Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease

Published on: September 21, 2022 View the full News here; Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights.

MDS 2022 Poster – An automated AI-based framework for putamen volume measurement in Multiple System Atrophy

EHDN Imaging Working Group Presentation on new HD-IH Consortium

• Category: Organisational News
• Date: 10/05/2022

Engagement in New Consortium in Huntington’s disease

Published on: 10th May 2022 View the full News here; Engagement in new consortium in Huntington’s disease About IXICO | Advanced Analytics | Intelligent Insights. IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis.

CHDI's 17th Annual Therapeutics Conference: The Future of Huntington's Research

CHDI’s 17th Annual Therapeutics Conference: Event ReviewBy Ronald Ramos (Senior Director, Business Development) and Kirsi Kinnunen (Senior Biomarker Scientist) CHDI’s 17th Annual HD Therapeutics Conference finally returned to a full, in-person event for the first time since 2020.

GAP-Net Site Optimization Conference 2022: Event Review

The Global Alzheimer's Platform Foundation’s GAP-Net Site Optimization Conference 2022 gave all participants an update on the important Bio-Hermes trial which is going very well. This year’s conference was a highly collaborative event with many interesting presentations and discussions on issues related to research in Alzheimer’s Disease.

IXICO & GAP Foundation: Alzheimer’s & The Bio-Hermes Study

Interview with IXICO & GAP Foundation: Alzheimer’s Disease & the Pioneering Bio-Hermes StudyAlzheimer's disease is an irreversible, progressive brain disorder that accounts for about 50–75% of all cases of dementia. It’s a growing problem. The USA saw a 145% increase in Alzheimer’s disease-related deaths between 2000 and 2018.

Discover IXIQ.Ai | IXICO's AI-Based Brain Segmentation Platform

What is IXIQ. Ai? Find out from our Chief Scientific Officer Robin WolzThis month, we launch into production on its first clinical trials. IXIQ. Ai is the next generation of our technology platform which we have been developing for more than a decade.